Gene/Cell Therapies: Still Just A ‘Science Project’?
This article was originally published in PharmAsia News
Executive Summary
While an increasing number of South Korean biotech firms are looking to advance into overseas gene and cell therapy markets as part of the government's plan to develop these areas as a new growth engine, a U.S. regulatory expert has cautioned it is risky for bioventures to focus only on the gene and cell sectors while they still face major regulatory and commercialization hurdles.
You may also be interested in...
Gene Therapy’s Roller Coaster Ride
With big pharma on board, disappointments like the threatened EU market removal of pioneering Glybera and the Celladon trial failure give the field of gene therapy a bumpy ride after some major highs.
Celladon’s Mydicar Fails In Phase IIb, But Don’t Count Out Gene Therapy
Shares of uniQure, Spark Therapeutics and bluebird bio all opened lower April 27 after Celladon announced its heart failure gene therapy Mydicar failed to show a benefit versus placebo in a mid-stage trial.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.